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ABSTRACT
The combination chemotherapy with fludarabine plus cyclophosphamide (FC) was compared to the standard regimen of fludarabine monotherapy in first line treatment of younger patients with chronic lymphocytic leukemia (CLL). Between 1999 and 2003 a total of 375 patients with predominantly advanced CLL younger than 66 years were randomized to receive either fludarabine (25 mg/m² for 5 days intravenously, repeated every 28 days) or FC combination therapy (fludarabine 30 mg/m² plus cyclophosphamide 250 mg/m² both for 3 days intravenously, repeated every 28 days). Both regimens were administered to a maximum of 6 courses. The FC combination chemotherapy resulted in a significantly higher complete remission rate (24%) and overall response rate (94%) compared to fludarabine alone (7% and 83%; P < .001 and P = .001). The FC treatment also resulted in a longer median progression-free survival (48 versus 20 months; P = .001), and a longer treatmentfree survival (37 versus 25 months; P < .001). So far, no difference in the median overall survival could be observed. FC caused significantly more thrombocytopenia and leukocytopenia, but did not increase the number of severe infections. In summary first line treatment with FC increases the response rates and the treatment-free interval in young patients with advanced CLL.
INTRODUCTION
The purine analogues cladribine and fludarabine are the most potent cytotoxic drugs currently available for the treatment of B-cell chronic lymphocytic leukemia (CLL).
Three phase III studies have shown that fludarabine is superior to chlorambucil and to a combination of cyclophosphamide, adriamycin and prednisone (CAP) regarding the number of complete remissions and the duration of remission in first and second line treatment of CLL [1] [2] [3] . However, none of these studies could demonstrate a benefit on median overall survival so far. Moreover, the relatively short progression-free survival of 25 to 32 months after a first line treatment with fludarabine is still unsatisfactory, especially for younger patients 2, 3 .
In vitro data showed that the exposure of CLL cells to fludarabine and cyclophosphamide resulted in an increased, synergistic cytotoxicity 4, 5 . The DNA repair mechanisms in CLL cells, which are initiated in response to cyclophosphamide exposition, are inhibited by fludarabine 6 . This observation was later translated into clinical trials. Results of phase II studies evaluating the combination of fludarabine plus cyclophosphamide (FC) showed very promising efficacy with response rates of more than 90% in previously untreated and pretreated patients [7] [8] [9] [10] [11] .
In 1999 the German CLL Study Group (GCLLSG) initiated a prospective multicentre phase III trial, comparing fludarabine alone with the combination FC in first line therapy of CLL patients below the age of 66 years. Here, we report the results on the efficacy and safety of the two regimens. The protocol has been approved by the institutional review board of the University of Munich. All patients had signed an informed-consent form before inclusion in the trial.
Randomization and treatment schedule
The randomization was performed by 
Response assessment
After every course of therapy patients were evaluated by clinical examination and blood count. After 3 and 6 courses of chemotherapy response assessment by clinical examination, blood count, serum chemistry, ultrasound examination or computed tomography (CT) and bone marrow biopsy for confirmation of complete response was performed. Patients who still had signs of toxicity after 3 courses of treatment were reassessed 3 months later. During follow-up response was assessed every three months by clinical examination, blood count and -if clinically indicatedultrasound examination.
The clinical response was defined according to the guidelines of the NCI-sponsored workshop 12 . Complete remission was defined as normal physical examination, disappearance of all symptoms and normal blood count, defined as lymphocytes less than 4. 10 9 /L, neutrophils more than 1.5 10 9 /L, platelets more than 100 10 9 /L, hemoglobin (untransfused) more than 110 g/L, as well as bone marrow lymphocyte percentage less than 30% in aspiration and biopsy. Moreover we evaluated complete remission with imaging diagnostics (CR with imaging), which had to be negative for any lymph node enlargement (enlargement was defined more than 1 cm 12 ), splenomegaly (defined more than 12 cm diameter in length) or hepatomegaly (more than 1cm below costal arch or more than 14 cm medioclavicular). Unconfirmed complete remission (uCR) was defined as complete remission in a patient, for whom 
Dose modifications
Toxic effects of the treatment were evaluated according to the Common Toxicity 
Statistical analysis
The study was initiated in July 1999, and recruitment was stopped in July 2003. A total of 375 patients were enrolled. Statistical analysis was performed on an intent-totreat basis including the eligible patients. The analysis presented here was based on the data collected by 7th of December 2004.
Time to event was estimated using the Kaplan-Meier method and treatment comparison was tested with the log-rank test. Overall survival was calculated from the randomization time point to death, progression-free survival from randomization
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Response rates were calculated for all patients with at least one cycle of therapy.
Treatment arms were compared by the chi-square test. Myelotoxicity was also assessed according to the NCI-sponsored Workshop guidelines 12 . All statistical tests were two-sided. Statistical significance was defined as p values less than 5%. The analysis was performed with SPSS V12.0.
RESULTS
Baseline characteristics of patients
375 patients were randomized within this study. 13 patients had to be excluded due to a violation of inclusion criteria (4 patients due to wrong diagnosis, 3 because of missing consent forms and 6 because of concomitant disease). 182 patients were randomized to receive fludarabine alone, 180 to receive FC. Eleven patients were lost for follow up. Survival data were available in 351 patients, response data in 328 patients and toxicity data in 346 patients.
When comparing patients in the two treatment arms, there was no significant difference regarding the main clinical features and risk categories (Table 1) . A median number of 6 courses were administered in both treatment arms: 70.7%
versus 64.0% of the patients completed 6 courses in the fludarabine and FC arm, respectively. The major reasons for an earlier treatment withdrawal in 51 patients from the fludarabine arm were non-response (33%), autoimmune hemolysis (23%) and toxicity (14%) including infections, myelotoxicity or skin reactions. FC therapy was stopped earlier in 63 patients because of toxicity (30%), partial or complete response (13%) or non-response (9%).
Response to treatment
Response data were available in 164 patients from each treatment arm. The FC treatment induced more complete remissions than the fludarabine treatment (P <
.001) and a higher rate of overall responses (P = .001) ( Table 2) . We also assessed the complete response rates with imaging as defined by blood count, bone marrow biopsy and negative imaging techniques. FC resulted in a complete remission rate with imaging of 16.5% versus 4.9% with fludarabine alone (P = .001). When including the number of unconfirmed complete remissions (uCR), the FC regimen yielded an uCR rate of 36.0%, as compared to 18.3% for fludarabine (P < .001). The superiority of the FC treatment was most prominent for Binet stage C patients, resulting in a 96.2% overall response rate with 13.2% complete remissions compared to 76.8%
overall response with fludarabine and without any complete response (Table 2 ). An univariate analysis showed, that gender, age, elevated serum thymidine kinase (s-TK) levels above 10 U/L and elevated serum ß 2-microglobulin levels (cut off level at 3.5 mg/dl) did not have any impact on response rates (data not shown).
Overall survival
The median time of follow-up was 22 months. There was no significant difference in overall survival between the two treatment arms, with a three year survival rate of Fifteen of 20 deaths in the FC arm were CLL-associated versus 9 of 17 deaths in the fludarabine arm (P = .51). Three patients in each treatment arm developed secondary aggressive lymphoma (overall incidence rate 1.7%). Deaths due to
Richter's syndrome were documented in three fludarabine-treated patients, and one FC treated patient died. In total, five therapy associated deaths occurred.
Progression-free survival and treatment-free survival
The median progression-free survival was significantly longer in the FC arm (48 months versus 20 months; P = .001) (Figure 2 ). FC treatment was also superior to fludarabine alone with regard to the progression-free survival in Binet B patients (17 months versus 45 months; P = .001). However, in Binet stages A and C the progression-free survival was not different in both arms. 76 pts with s-TK levels of ≤ 10 U/L, were compared to 190 patients with s-TK levels > 10 U/L. Median progression-free survival was 27 months for patients with elevated s-TK levels, and was not reached in patients with low levels (P = .09). No significant difference in progression-free survival was assessed in patients with elevated versus low serum ß 2-microglobulin levels (cut off level of 3.5 mg/dl). Progression-free survival was similar in patients with 60 years or older compared to patients younger than 59 years as well as in male and female patients.
FC treatment resulted in a significantly longer treatment-free survival time (37 months) compared to fludarabine (25 months) ( Figure 3 ).
For
org From
Response to second line treatment 32 FC and 59 fludarabine treated patients received relapse treatment. Response data were available in 23 and 54 patients, respectively. The overall response rate to second line treatment was 69.6% in the primarily FC treated group and 73.6% in the fludarabine treated group (P = .72).
Six of 9 patients without response to FC, received relapse treatment immediately afterwards. Four of them did not respond to relapse treatment as well, in the two remaining patients data on response to second line treatment were not available.
Toxicity
Data on toxicities were available from 173 patients in each treatment arm. Treatmentrelated mortality was recorded in five patients (1.4%). Two patients died of treatmentrelated side effects in the FC arm (one of severe autoimmune haemolytic anemia and thrombocytopenia, one of tumor lysis syndrome), 3 in the fludarabine arm (one patient of pneumonia with sepsis, one of a cerebral bleeding due to thrombocytopenia and one of autoimmune hemolytic anemia). Myelotoxicity was the major side effect in both arms. Both mild (CTC grade 1 and 2) and severe (CTC grade 3 and 4) myelotoxicity and in particular leukocytopenia were significantly more frequent in the FC arm (Table 3) . When evaluating treatment-related anemia and thrombocytopenia according to the NCI criteria, severe thrombocytopenia (grade 3 and 4, indicating a more than 50% decrease of platelet counts), was also significantly more frequent in the FC arm ( Table 3 ). The rate of severe infections as well as the incidence of opportunistic infections was similar in both treatment arms. In each treatment arm one case of fungal pneumonia occurred, in the FC arm one additional case of gastrointestinal tuberculosis was observed. Furthermore gastrointestinal side 
DISCUSSION
The results of this multicentre phase III trial show that a combination therapy consisting of fludarabine plus cyclophosphamide is more efficacious when compared to fludarabine monotherapy in the first line therapy of CLL. FC treatment improved the overall response rate, the complete remission rate, the progression-free survival time and treatment-free survival time.
Preliminary results of an Intergroup trial comparing FC with fludarabine alone showed similar results on the superiority of FC 15 . However, the overall response rates in this
Intergroup trial were lower compared to our study, which might be due to a higher proportion of elderly patients or the inclusion of a higher proportion of high risk patients 15 .
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From It is noteworthy that in this study the rate of true complete remissions was lower in both treatment arms than in some studies published previously. Complete remission rates of 20% to 40% were reported for fludarabine used as first line therapy in two phase III trials 2, 3 . In our study, the complete remission rate was only 7% in the fludarabine arm. Similarly, higher complete remission rates of 35% to 49% were reported for FC if used as first line therapy 7, 9, 11 compared to 24% complete remissions in our study. One explanation for this difference is that more advanced We also assessed the complete remission rate including imaging procedures as CT scan and ultrasound examination which were performed during the final staging in all patients in this study. Especially with the FC treatment the complete remission rate was significantly lower when imaging procedures were used (16% versus 24% and 5% versus 7%). In the 1996 NCI response criteria the role of imaging diagnostic is not clearly defined. These criteria state that "absence of lymphadenopathy by physical examination and appropriate radiographic techniques" is needed for confirmation of complete remission 12 .Our results support the need for a revision of these criteria with regard to modern imaging procedures by showing that the response rates vary considerably when using CT or ultrasound imaging. In 5 out of 9 patients who did not respond to FC a 17p deletion was observed, which predicts a poor prognosis and resistance to treatment in CLL [16] [17] [18] . In the future, alternative treatment strategies are needed (alemtuzumab, allogeneic stem cell transplantation). A cytogenetic analysis of all patients of the CLL4 protocol will show, if response to therapy can be determined by FISH.
The FC treatment resulted in a progression-free survival time of 48 months. Similar results on progression-free survival have been reported previously 11, 15 . The difference in time to progression between the two treatment arms was 28 months. It remains to be seen, how the two-year progression-free survival rate of 67% obtained with the FC regimen compares to combinations consisting of fludarabine with the antibody rituximab, for which similar progression-free survival rates have been reported 19 .
The fact that the progression-free survival for FC and fludarabine was not different for patients in Binet stage A can be explained by the small size of the group of patients, which reduced statistical power. The lack of difference in the progression-free survival in Binet stage C patients might be explained by the short observation period, since only 48 of 115 patients (42%) in Binet stage C had progressive disease or died so far.
So far, no difference between fludarabine alone and FC was observed with regard to overall survival. The median observation time of 22 months was too short to validate a survival difference between fludarabine alone and FC treatment. Similarly none of
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From the previously published phase III trials was able to show a significant survival advantage for any of the first line therapies 2, 3 . Because the recurring nature of indolent lymphomas routinely requires subsequent therapies, which modify the clinical course of the disease, an overall survival benefit by a more effective first line treatment strategy is often difficult to prove.
Relapse treatment options in CLL patients range from chlorambucil to allogeneic stem cell transplantation. The inconsistency in relapse strategies is one of the explanations for the lack of survival benefit after FC therapy. Therefore, future trials should contain specific advice for second and third line treatment strategies in CLL patients if possible. Moreover and more importantly, a longer median observation times is needed to determine a survival benefit for any first line regimen.
A third reason for the missing survival benefit in the FC arm might be an impaired response to second or third line treatment. No difference in overall response to second line therapy was observed between the two treatment arms in this trial. But we cannot exclude at the present time that FC treatment selects for more resistant cell clones. In this study no blood samples for cytogenetic aberration in follow up were obtained. Therefore, one can only speculate whether FC induces additional genetic aberrations in CLL.
An overall incidence rate of 1.7% of secondary aggressive lymphomas was observed in this trial. Previously published studies reported incidence rates of 3% to 12%
Richter's transformation [20] [21] [22] . Treatment with fludarabine is accused to have a major impact on an increased incidence of transformations of up to 12% in CLL due to its immunosuppressive effects 22 . The rate of Richter's transformation in our trial was relatively low, probably related to the short observation period. However, no difference in the rate of secondary aggressive lymphomas was observed between the two treatment arms.
The FC combination caused more side effects, in particular myelotoxicity. In spite of the higher rate of severe leukocytopenia in the FC arm, the incidence of severe infections was similar in both treatment arms. A possible explanation is that the FC dose was more frequently reduced or delayed than fludarabine. Compared to other studies 9,11 the incidence of infections in patients treated with FC within this trial was relatively low. However, a lower dose of cyclophosphamide was used in this trial, and the patients included in this trial were younger than in previous phase II trials using FC 11, 15 .
Another important side effect of fludarabine is the occurrence of autoimmune cytopenias which are sometimes severe or even lethal. There was a trend for a higher incidence of AIHA in general in the fludarabine arm, which might be related to the lower dose of fludarabine within the FC regimen or to some protective effects of cyclophosphamide. Similar results have been reported by the UK CLL study group 23 .
In summary, the FC combination yields significantly higher response rates and a longer progression-free survival and treatment-free survival than fludarabine alone.
With regard to the progression-free survival and the treatment-free survival this phase III study shows the largest difference of two treatment regimens, which has ever been reported in CLL. The FC therapy can be given with acceptable side effects. The GCLLSG will therefore use FC as standard first line therapy in CLL patients who are physically fit. It remains to be seen whether this regimen allows to prolong the overall survival time of patients with advanced CLL.
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